Ardelyx was founded in 2007 by Dominique Charmot, Ph.D., Peter Schultz, Ph.D. and Jean Frechet, Ph.D., to discover, develop and commercialize innovative, non-systemic, small molecule therapeutics that work exclusively in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. We have developed a proprietary drug discovery and design platform enabling us, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing our platform, we discovered and designed our lead product candidate, tenapanor, which in preclinical and clinical studies has consistently demonstrated the ability to reduce the absorption of dietary sodium and phosphorus, both of which are key factors in the progression of kidney disease.
We are developing our lead product candidate, tenapanor, for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. We are also developing RDX022 for the treatment of high potassium, or hyperkalemia, in kidney and heart disease patients.
To enhance our proprietary drug discovery and design platform, we have developed a cell-culture system to simulate gut tissues called Ardelyx Primary Enterocyte and Colonocyte Culture System (APECCS). In addition to tenapanor, we are evaluating small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in ESRD, a program we have licensed to Sanofi. We are also independently advancing our earlier stage discovery and lead development programs focused in GI and cardio-renal diseases.